October 4, 2016

AngioSoma's Joint Venture Will Pursue FDA Approval of Liprostin for PAD

October 5, 2016—AngioSoma, Inc. announced a joint venture with La Jolla Capital Partners LLC to focus on funding and management of US Food and Drug Administration (FDA) phase 3 clinical trials and subsequent worldwide licensing for the company’s flagship product, Liprostin, a liposomal encapsulated prostaglandin E1.

AngioSoma is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, particularly those related to endovascular interventions in the treatment of peripheral artery disease (PAD). Liprostin has been evaluated for the treatment for PAD in a successfully completed FDA phase 1 trial and three phase 2 clinical trials. The company is now completing the FDA-approved protocol for the phase 3 trial with submission of a new drug application for marketing in the United States and its territories, stated AngioSoma.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

October 4, 2016

AngioSoma's Joint Venture Will Pursue FDA Approval of Liprostin for PAD

Current Issue

Keep In Touch